Pan-Asian adaptation of the 2025 ESMO guidelines on diagnosis, treatment and follow-up of hepatocellular carcinoma, agreed by experts from oncology societies in 10 Asian countries/regions; voting was evidence-based and independent of local drug access and reimbursement.
Guideline
Tan et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment, and follow-up of patients with hepatocellular carcinoma